Profit

Cadila Settles Patent Litigation Related To Livalo Tablets

 Share
EMAIL
PRINT
COMMENTS
Cadila Settles Patent Litigation Related To Livalo Tablets
New Delhi: Drug firm Cadila Healthcare has settled all outstanding patent litigation related to Livalo tablets with Kowa Company, Kowa Pharmaceuticals America Inc and Nissan Chemical Industries Ltd.

The company and its subsidiary, Zydus Pharmaceuticals (USA) Inc, have finalised an agreement with Kowa Company, Kowa Pharmaceuticals America Inc and Nissan Chemical Industries to settle all outstanding patent litigation regarding Livalo (pitavastatin calcium ) tablets, Cadila Healthcare said in a filing to BSE.

"Under the terms of the agreement, Kowa and Nissan grant Zydus a licence to market Zydus' generic version of Livalo beginning on May 2, 2023, or earlier under certain circumstances," it added.

Other terms of the settlement were however not disclosed.

Livalo tablets are indicated as an adjunctive therapy to diet  to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia.

Ahmedabad-based Zydus group employs over 19,500 people worldwide.

(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)


Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.

NDTV Beeps - your daily newsletter

................................ Advertisement ................................

................................ Advertisement ................................

................................ Advertisement ................................

Top